Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Observational Model: Cohort, Time Perspective: Prospective
Rate of complete molecular response (CMR) after treatment with dasatinib
The rate(%) of patients who achieve complete molecular response (CMR) by 18 months after the dasatinib therapy will be measured to evaluate the efficiency of dasatinib.
by 18 months
Japan: Institutional Review Board